AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02035085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1000 labeled SVF cells
Description: Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 386
Description: AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone
Description: A 1,000 mg dose of abiraterone should be taken orally once daily
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
Study NCT01553188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
Study NCT04207801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Inhibitor of RORγ
Study NCT04207801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug-Placebo of AUR101 tablet
Study NCT02403570 — intervention group
Intervention type: OTHER
Intervention: Brain MRI
Study NCT03669432 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System.
Study NCT03669432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery alone
Description: This intervention is of no interest
Study NCT03669432 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: This intervention is of no interest
Study NCT03679611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
Study NCT03679611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
Study NCT03625167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with petrolatum
Description: Petrolatum is applied twice daily to the intervention arm.
Study NCT00651417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Organic Germanium
Description: Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
Study NCT00651417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets orally 3 - 5 times per day as tolerated
Study NCT02975466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of AirQ Blocker and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation
Study NCT02975466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of AuraGain and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation
Study NCT02975466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of I-Gel and intubation through the device
Description: Insertion of the SGA device and evaluation of easiness of endotracheal intubation
Study NCT01968252 — intervention group
Intervention type: OTHER
Intervention: Concurrent TTE and TEE
Description: All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
Study NCT01483508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol- and procyanidins-containing drink
Description: Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]
Study NCT01483508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procyanidins-containing drink
Description: Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]
Study NCT01483508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-containing drink
Description: Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
Study NCT02501057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician's Guide
Description: An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
Study NCT02501057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Motivational Interviewing
Description: Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
Study NCT02501057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Clinician's Guide
Description: An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
Study NCT03918798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1% Injectable Solution
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Study NCT03918798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 2% Injectable Solution
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Study NCT02968888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Study NCT02968888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study NCT02968888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk 1%
Study NCT02968888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate 80
Study NCT02968888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey
Study NCT02032368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Study NCT00625911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: intravenous patient controlled analgesia, standard protocol
Study NCT00625911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine ketamine
Description: low dose ketamine added to 2/3 standard dose of morphine
Study NCT03054103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam + Ketamine 10 MG/ML: 0.5 ML
Description: 5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Study NCT03054103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam + Ketamine 10 MG/ML: 1 ML
Description: 10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Study NCT03054103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam + Normal saline
Description: Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
Study NCT00769106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cell (CIK) treatment
Description: cytokine-induced killer cell treatment every two weeks, for 4 cycles
Study NCT01229085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memotasone + salicylic acid
Description: mometasone 0,1% + salicylic acid 5%.
Study NCT00004193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Study NCT04682041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Plasma-Derived Immunoglobulin Concentrate
Description: EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
Study NCT04682041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care PSMAR protocol for COVID-19 patients.
Study NCT04682041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care PSMAR protocol for COVID-19 patients.
Study NCT03184441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premie Pouch
Description: The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
Study NCT01967108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: chest physiotherapy, up to one hour from extubation, in ICU patients
Study NCT02447900 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioXmark
Study NCT00265759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT00265759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT00265759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study NCT00265759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
Study NCT02270736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201 Placebo
Description: NT 201 placebo matching injection.
Study NCT02270736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: NT 201 injection.
Study NCT01993875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
Study NCT01993875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of cognitive reserve, depression, personality traits and leisure activities
Description: In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS).
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical-neuropsychological follow-up
Description: For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
Study NCT05569083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ERP recording
Description: For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
Study NCT01940471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily
Study NCT01940471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT01940471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily
Study NCT01940471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: Tablet administered orally once daily
Study NCT00627887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
Study NCT00627887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: extended release target dose of 300mg/day duration of one year
Study NCT00627887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: extended release target dose of 300mg/day duration of one year
Study NCT00627887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: serum concentration 0,5-0,8 mmol/L, one year duration
Study NCT00627887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: serum concentration 0,5-0,8 mmol/L, one year duration
Study NCT01120392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment with Nintendo wii.
Description: Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
Study NCT01120392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy conventional.
Description: Conventional exercises used with the same goals for the group with wii
Study NCT03811457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Welgenaleucel
Description: Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
Study NCT02591381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial Urinary Sphincter Placement
Description: The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
Study NCT00615472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Study NCT00615472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Study NCT00615472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Study NCT00904631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eraser device+ salicylic acid (5%)
Description: Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
Study NCT00492427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.
Study NCT00492427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: 6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
Study NCT01050452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole
Description: albendazole (400 mg on dose)
Study NCT01050452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole
Description: mebendazole (500 mg one dose)
Study NCT01050452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: ivermectin (200 microgram/kg body weight)
Study NCT01050452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole + ivermectin
Description: albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
Study NCT01050452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mebendazole + ivermectin
Description: mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
Study NCT01120548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation therapy
Description: The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient.
Study NCT01001468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: Single daily dose of oral VB-201 20 mg
Study NCT01001468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: Single daily dose or oral VB-201 80 mg
Study NCT01001468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single daily dose of oral placebo
Study NCT04133454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV-hTERT
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration